Two recent CRISPR-Cas9 viability screens in cancer cell lines were concordant across multiple metrics despite significant differences in experimental protocols.
The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.